Document Detail

Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues.
MedLine Citation:
PMID:  23286858     Owner:  NLM     Status:  In-Data-Review    
Interferon alpha has restricted efficacy in as much as only a proportion of patients show a response. However, in appropriately selected HBeAg-positive and HBeAg-negative patients, sustained suppression of viral replication can be achieved, and HBeAg or even HBsAg seroconversion can be attained. Thus, finite course of interferon alpha can be successful, and offer an advantage to patient. Interferon (IFN) remains a benchmark therapy for chronic hepatitis B. The main advantages of IFN-α over nucleoside analogues are the absence of resistance and the possibility of immune-mediated clearance of hepatitis B. Unfortunately, side effects preclude the use of interferon alpha in substantial proportions of patients, and prolonged maintenance therapy to suppress hepatitis B virus (HBV) is not feasible. Nucleoside analogues are given by mouth, once per day, and the safety, potency and efficacy have improved and facilitated treatment. However, maintenance of long-term suppression is required for the majority of patients. In general, treatment of chronic hepatitis B should target patients with active disease and viral replication, preferably before the signs and symptoms of cirrhosis or significant injury has occurred. Current EASL guidelines suggest that treatment be based on the evaluation of three criteria: Serum aminotransferase levels, serum HBV DNA levels and histological grade and stage. Many questions remain unanswered on the optimal treatment of patients with chronic hepatitis B with a nucleoside vs interferon alpha. Both forms of treatment have benefits and the choice should be selected and tailored. Stopping or futility rules can be implemented in patients who fail interferon. Recent data suggest the safety and efficacy of nucleoside analogues in the third trimester of pregnancy to reduce the risk of transmission from mothers to their children.
Geoffrey Dusheiko
Related Documents :
23235088 - Why don't we treat chronic hepatitis c in hiv patients? results from a cohort of hiv-hc...
24283228 - Case 37-2013.
23526668 - Liver transplantation in hepatitis b core negative recipients using livers from hepatit...
23745368 - Results of liver transplantation in the department of general, transplant and liver sur...
20051008 - Persistent and transient hepatitis b virus (hbv) infections in children born to hbv-inf...
22783698 - Levels of felt stigma among a group of people with hiv in puerto rico.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Liver international : official journal of the International Association for the Study of the Liver     Volume:  33 Suppl 1     ISSN:  1478-3231     ISO Abbreviation:  Liver Int.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-04     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160857     Medline TA:  Liver Int     Country:  United States    
Other Details:
Languages:  eng     Pagination:  137-50     Citation Subset:  IM    
Copyright Information:
© 2012 John Wiley & Sons A/S.
UCL Division of Liver and Digestive Health, University College London Medical School, and Royal Free Hospital, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Why do I treat HBeAg-positive chronic hepatitis B patients with a Nucleoside analogue.
Next Document:  Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues?